In recent years, there are many well-recognized molecular determinants of immunotherapeutic responsiveness, including PD-L1 expression on tumor (13), microsatellite instability (14), tumor mutation burden (TMB) (15), neo-antigen load (16), and tumor infiltrating lymphocytes (TILs) (17). Here, CD274 is linked to neoplasm.